RxDoctor Payments Data

Sunil Abhyankar, MD

Hematology & Oncology · Westwood, KSNPI 1972575488

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Incyte Corporation accounts for 60.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $44,184 and has fallen 72.4% since, to $12,177 in 2025. Among hematology & oncology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$78,121in general payments, 2019–2025

Across 68 payments — averaging $1148.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$47K
  • Mallinckrodt Enterprises LLC$17K
  • CSL Behring$9K
  • Gilead$5K
  • Genmab U.S., Inc.$124
  • Carl Zeiss Meditec, Inc.$104
  • plus $125 from 4 others
$4,956,917in research payments, 2019–2025

Across 442 payments — averaging $11,215 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Jazz Pharmaceuticals Inc.$2.5M
  • CSL Behring$1.7M
  • Incyte Corporation$346K
  • Genentech, Inc.$158K
  • National Marrow Donor Program$152K
  • Deciphera Pharmaceuticals Inc.$110K
  • plus $32K from 4 others

What the payments were for

  • Consulting fees$27,13435%
  • Speaking & faculty fees$34,24844%
  • Travel & lodging$15,21019%
  • Food & beverage$1,5162%
  • Education$140%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,121 in reported general payments places this provider in the 90th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$137,625
Medicare patients
246
Services billed
1,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Posaconazole20$21,083
Atovaquone15$6,964
ArexvyRsvpref3 Antigen/As01e/Pf11$2,862
Acyclovir116$2,505
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,141
Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf11$1,878
Ursodiol15$1,656
PentacelDipht,pert(A),tet-Polio/Hib/Pf16$1,606
Fluconazole18$1,038
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim104$646
Penicillin V Potassium35$631
Hydrocortisone19$619
Dapsone12$523
Gabapentin29$486
Potassium Chloride19$452

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Westwood

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →